Business
Investor Evening
Investor Evening.
About this update from Avacta Group Plc
[{"type":"text","content":"\n \nRNS Number : 1344U Avacta Group PLC 05 April 2016 \n\n05 April 2016\n \nAvacta Group plc\n(\"Avacta\" or \"the Group\" or \"the Company\")\n \nInvestor Evening - Thursday 5 May 2016\n \nA discussion of its proprietary Affimer technology and an update on commercial and therapeutic strategies\n \nAvacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and research reagents, is pleased to announce that it will be hosting an investor evening at the offices of FTI Consulting, 200 Aldersgate, Aldersgate Street, London, EC1A 4HD, on Thursday 5 May 2016 from 17.00-20.30 BST. The Company will discuss its proprietary Affimer technology and provide an update on the progress made against its commercial and therapeutic goals. Chief Executive Officer Alastair Smith will be joined by Philippe Cotrel, Amrik Basran, Matt Johnson and Tony Gardiner from the Company's Senior Leadership Team.\n \nDrinks and canapés will be served following the Company's presentations.\n \nFor further information and to reserve a place at the event please contact: [email protected] \n \n \nEnquiries:\n\n\n\n\nAvacta Group plc\nAlastair Smith, Chief Executive Officer\nTony Gardiner, Chief Financial Officer\n \n\n\nTel: +44 (0) 844 414 0452\nwww.avacta.com \n\n\n\n\nNumis Securities Limited \nMichael Meade / Freddie Barnfield - Nominated Adviser\nJames Black - Corporate Broking\n \nWG Partners\nDavid Wilson\nNigel Barnes\nClaes Spang\n \n\n\nTel: +44 (0) 207 260 1000\nwww.numiscorp.com\n \n \nTel: +44 (0) 203 705 9318\nTel: +44 (0) 203 705 9217\nwww.wgpartners.co.uk\n \n \n\n\n\n\nMedia Enquiries\nFTI Consulting\nSimon Conway / Natalie Garland-Collins\n\n\nTel: +44 (0) 203 727 1000\[email protected] \n\n\n\n\n \n \nNotes to Editors\n \nAvacta Group plc (www.avacta.com)\n \nAvacta's principal focus is on its proprietary Affimer® technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development.\n \nAntibodies dominate these markets, worth in excess of $75bn, despite their shortcomings. Affimer technology has been designed to address many of these negative performance issu...